@article{e179ede9d81a489eb1c75241a2313052,
title = "Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.",
author = "Ivaylo Gentschev and Marion Adelfinger and Rafael Josupeit and Stephan Rudolph and Klaas Ehrig and Ulrike Donat and Stephanie Weibel and Chen, {Nanhai G.} and Yu, {Yong A.} and Qian Zhang and Martin Heisig and Douglas Thamm and Jochen Stritzker and Amy Macneill and Szalay, {Aladar A.}",
note = "Funding Information: The authors have read the journal's policy and have the following conflicts: IG QZ YAY NGC JS and AAS are employees and shareholders of Genelux Corporation. MA, KE and SW were supported by grants of Genelux Corporation. Sequences of the two Lister Vaccinia virus strains (LIVP1.1.1 and LIVP5.1.1.) tested in this study are subject of the patent application {\textquoteleft}Clonal strains of attenuated vaccinia viruses and methods of use thereof (U.S. Application No. 61/517,297){\textquoteright}. There are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors ( http://www.plosone.org/static/policies.action#sharing ). The authors do not have any other relevant declarations relating to employment, consultancy, patents, products in development or marketed products, etc. The title and the permit number for the patent are: {\textquoteleft} Clonal strains of attenuated vaccinia viruses and methods of use thereof (U.S. Application No. 61/517,297){\textquoteright}. ",
year = "2012",
doi = "10.1371/journal.pone.0037239",
language = "English",
volume = "7",
pages = "e37239",
journal = "PLoS ONE",
issn = "1932-6203",
number = "5",
}